C hronic obstructive pulmonary disease (COPD) is considered a global health issue (1) . In Denmark, an estimated 400,000 subjects have COPD (2) , and COPD is annually responsible for more than 20,000 acute hospital admissions (3) .
Non-invasive ventilation (NIV) as an add-on modality to medical treatment is recommended in national guidelines for patients acutely admitted with COPD exacerbation and hypercapnic respiratory failure (4) . This recommendation is based on randomized controlled trials showing lowered mortality rates in highly selected patients (5) and subsequent expert interpretation (6) . A nationwide COPD quality improvement program Á DrKOL, formerly NIP-KOL Á was launched in Denmark in 2008, where data on the use of NIV and mortality have been monitored in patients acutely admitted with a COPD exacerbation. In this program, recently published data show regional variations in practice (7) .
In the region of Southern Denmark, the ratio of acutely admitted COPD patients with exacerbation receiving NIV has been consistently higher than in other regions in Denmark throughout the years of registration (8) . This practice has been partly explained by early implementation of NIV in the Respiratory and Medical Emergency , allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.
Wards in the region, locally initiated targeted introductions to guidelines recommending this treatment modality, and consistent ICD-10 (International Statistical Classification of Diseases and Related Health Problems, 10th revision) coding practice (9, 10) . In England, initial data on the mortality of COPD patients admitted with an exacerbation did not show improved survival after the publication of guidelines supporting the use of NIV, and a multicenter audit revealed that NIV was often given to patients outside indications, and that patients fulfilling criteria for treatment with NIV did not receive NIV treatment (11) .
To address concerns on whether or not NIV is provided appropriately, we undertook an audit of all COPD patients admitted to a Medical Emergency Ward and a Respiratory Ward at Odense University Hospital, Denmark, in 2010. The aims of this study were 1) to evaluate if COPD patients with criteria for NIV therapy received the treatment according to local and national guidelines, and 2) if patients receiving NIV also fulfilled criteria of having COPD and respiratory acidosis.
Methods
Two cohorts of patients admitted in 2010 were retrieved: Table 1 . Admissions are presented in order to demonstrate that readmissions were more frequent in patients with the lower spirometry measures and use of LTOT. Current smoking was registered in 31.1% of the patients. Of the 521 patients, 71 (13.6%) had no comorbidities, 62 (11.9%) had one, 116 (22.3%) had two, and 272 (52.2%) had three or more listed in their medical records. In this acute cohort, NIV treatment was initiated in 151 (18.7%) of the 804 admissions. Evaluation of admissions revealed 42 additional admissions (5.2%) in which arterial blood gas analyses fulfilled criteria for NIV. In most admissions (36), initial arterial blood gas analysis showed respiratory acidosis, but later analyses or evaluations of clinical states were either described as improved (28) or not commented on at all (8) in the patient records. No deaths occurred within the registered 30 days following these 36 admissions. In four admissions, NIV treatment was not initiated due to patients' inability to cooperate or refusal, and two of these patients subsequently died, one patient within three months and the other 2.5 years later.
In the last two cases, NIV treatment was considered futile, and both patients subsequently died in hospital. In the group of 151 patients in whom NIV was initiated, treatment in nine patients was abandoned quickly due to a 'not-to intubate' order or later refusal. These admissions have been categorized as adequate treatment choices. Thus, 157 admissions (81.3%) out of 193 admissions fulfilling the indication for NIV were correctly evaluated, and 151 admissions (78.2%) were subsequently treated with NIV acutely.
In the second cohort, which comprised patients receiving NIV during an admission to the Respiratory Ward in 2010, 124 NIV treatments in 105 unique patients were registered. A total of 91 patients received NIVonce, 10 twice, 3 three times, and 1 four times. NIV was initiated with registered blood gas analyses pHB7.35 and pCO 2 6.0 kPa in 104 cases (83.9%), and in 21 cases (19.3%) drowsiness was noted.
In this cohort, 93 treatments were initiated in patients also registered in DrKOL with ICD-10 codes, as described in this article. Fourteen treatments were initiated in patients who were subsequently discharged without a diagnosis of COPD, and in the remaining 17 admissions, COPD patients either were registered at the Respiratory Ward when being admitted directly to the Intensive Care Unit (ICU) or had another primary diagnosis than COPD (DJ44), pneumonia (DJ13ÁDJ18), or respiratory failure (DJ96). Demographic data presented in Table 2 as patients and admissions with a diagnosis of COPD compared to patients without a diagnosis of COPD. All patients registered without COPD and treated with NIV had only a single admission in the Respiratory Ward.
In four admissions, NIV was given in the absence of hypercapnea (pCO 2 B6.0 kPa), and NIV treatment of all of these patients was categorized as inappropriate. Two of these patients treated had a 'not-to-intubate' order due to comorbidities (disseminated cancer and multimorbidity), and NIV was given as a last option; the other two were subsequently transferred to the ICU and intubated, and one patient died. The three patients without diagnosed cancer were elderly (79, 82, and 83 years), and only the patient with COPD survived.
Thus, for 103 (82.3%) of the 124 NIV treatments initiated, an indication of respiratory failure in COPD was documented.
The aim of this study has primarily been focused on the use of NIV treatment. Outcome data for COPD revealed treatment failure, defined as referral to the ICU, intubation, or death in patients presenting with an initial pH at 7.30 to 7.35 as 15% (3 of 20 patients), pH lower than 7.30 to 7.25 as 21.1% (8 of 38 patients), and pH lower than 7.25 with treatment failure in 36.7% (11 of 30 patients). 
Discussion
We present data on clinical practice and adherence to guidelines on NIV treatment to COPD patients presenting with exacerbation, and we found that 18.7% of patients admitted had received NIV treatment. A group of patients initially presenting with respiratory failure and mild acidosis (5.2%) were not treated with NIV, but in 36 of these 42 cases, an improved clinical status without supplementary ventilation support was documented. Few patients could not cooperate or refused treatment, but evaluation on whether these patients could have accepted NIV or benefitted from NIV treatment in another setting was not possible. The decision regarding NIV treatment was considered for patients presenting with respiratory failure and hypercapnea, and NIV was given in 14 patients without verified COPD, where the treatment was offered as the best option in over half of the cases having an order of 'not-to-intubate'. In four admissions, NIV treatment was initiated without hypercapnea, and the outcome for these admissions was categorized as 'failure' (referral to ICU or mortality). Confalonieri et al. (12) showed in a randomized trial in an ICU setting that NIV given to patients presenting with acute respiratory failure due to communityacquired pneumonia was superior to standard treatment (oxygen delivery in Venturi masks). Subgroup analysis showed that patients without COPD had lower measured pCO 2 levels (4.27 kPa versus 9.73 kPa in the COPD group), and no significant reduction of intubation need was found.
Although our cohorts comprised patients with considerable comorbidities, our reported treatment failure, defined as transfer to the ICU (including treatment with NIV) or mortality, was comparable to the reported outcome in a randomized trial with selected COPD patients (13) . Patients in our study with a pH level between 7.30 and 7.25 had a failure rate of 21.1%, and in the subgroup of patients with pH between 7.25 and 7.30 receiving NIV in the randomized trial, a failure rate of 36% was reported. Plant et al. showed that NIV treatment compared to standard treatment resulted in a significantly lower failure rate of 15% (NIV group) versus 27% (Standard), p00.02, and our data from a real-life setting support that the intervention with NIV reduces intubation need, and thus referral to ICU, in COPD patients presenting with hypercapnic respiratory failure. In our cohort, 30 patients were registered with an initial pH lower than 7.25; treatment failure was seen in 11 of these 30 patients (36.7%), and five of them were referred to the ICU. Failure rates and mortality rates were comparable to those of the randomized controlled trial in the COPD group with a pH lower than 7.30 at presentation, and we have therefore concluded that initiation of NIV to COPD patients with a pH lower than 7.25 is feasible and safe in the Medical Emergency Ward and Respiratory Ward. Our cohorts were primarily chosen firstly to try to include all COPD patients admitted to the Medical Emergency Ward and evaluate ICD-10 coding in clinical practice, and, secondly, to include all patients receiving NIV regardless of ICD-10. Corral-Gudino et al. (14) reported on a cohort of elderly COPD or cardiogenic pulmonary edema patients in Spain who had a 'not-to-intubate' order, and they concluded that use of NIV in general wards could be a safe and effective option, as a last-choice treatment. Not surprisingly, the outcome (survival at discharge) was better for COPD patients requiring NIV (63%) than for patients with acute cardiogenic pulmonary edema (55%), and this was also seen in survival rates after 1 year (50 and 37%, respectively). We have earlier reported longterm survival for COPD patients receiving NIV for the first time (10), and we found a 30-day mortality rate of 24.3%, but surprisingly a 5-year survival rate of 23.1%.
Conclusion
NIV is implemented at the Medical Emergency Ward and Respiratory Ward as an add-on treatment in patients presenting with hypercapnic respiratory failure due to a COPD exacerbation. NIV was initiated in 18.8% of the COPD admissions, and in an additional 5.2%, NIV criteria were met without initiation, and the results are considered appropriate. In 82.3% of the admissions in the Respiratory Ward receiving NIV, a COPD diagnosis and fulfilled criteria for NIV treatment were met. In 11.2% of the admissions, patients did not have COPD; and, in half, NIV was also used as a last-choice treatment in patients with respiratory failure.
